These include CD-19 targeting therapies, such as tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), and lisocabtagene maraleucel (Breyanzi), which have demonstrated exceptional efficacy in treating relapsed or refractory B-cell lymphomas and acute lymphoblastic leukemia (ALL) (4–7). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.